XML 83 R67.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Equity (Details) $ / shares in Units, $ in Thousands |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 01, 2023 $ / shares | Nov. 01, 2022 shares | Sep. 15, 2022 shares | Aug. 02, 2022 shares | Jun. 01, 2022 USD ($) shares | Jul. 21, 2021 shares | Mar. 04, 2021 | Mar. 02, 2021 shares | Nov. 30, 2020 shares | Oct. 01, 2020 shares | Apr. 01, 2020 | Aug. 18, 2023 $ / shares shares | Nov. 20, 2020 USD ($) shares | Oct. 16, 2020 shares | Sep. 17, 2020 shares | Jun. 30, 2023 $ / shares shares | Dec. 31, 2022 shares | Dec. 31, 2021 $ / shares shares | May 31, 2023 shares | Mar. 22, 2023 shares | Jun. 30, 2022 | Mar. 19, 2020 shares
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reverse split ordinary shares |  |  |  |  |  |  |  |  |  |  |  | 75,000,000 |  |  |  |  |  |  |  |  |  |
Ordinary shares no par value (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,798,840 | 3,091,740 |  |  |  |
Description of private offering |  |  |  |  | the Company completed a private offering with an investor for gross proceeds of $10,210 (the “June 2022 Private Placement”), providing for the issuance of an aggregate of 3,546,100 units and pre-funded units, as follows: (a) 335,000 units at a price of $2.88 per unit, each consisting of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the “June 2022 Warrants”), and (b) 3,211,100 pre-funded units at a price of $2.819 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) two June 2022 Warrants. |  | the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an aggregate of 1,152,628 units, as follows: (a) 916,316 units at a price of $7.07 per unit, consisting of (i) one ordinary share of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the “2021 Series A Warrants”) and a Series B Warrant (the “2021 Series B Warrants” and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase half the number of units, and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Date of issuance |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  | 5 years |  |  |  |
Ordinary shares issued |  | 37,000 | 75,000,000 | 24,000 |  | 6,000 |  |  |  | 40 |  | 75,000,000 |  |  |  |  |  |  |  |  |  |
Warrants and exercise |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 123,504 | 10,000 |  |  |  |
Pre-funded warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,211,100 |  |  |  |  |
Ordinary shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 123,504 |  |  |  |  | 314,285
Description of reverse share split |  |  |  |  |  |  |  |  |  |  |  |  |  |  | the Company convened a special general meeting of its shareholders, whereby the shareholders approved, inter alia, (i) an increase to the Company’s share capital from 500,000,000 ordinary shares to 750,000,000 ordinary shares; and (ii) a reverse split of the Company’s share capital up to a ratio of 20:1 (the “Reverse Split”). |  |  |  |  |  |  |
Purchase agreement, description |  |  |  |  |  |  |  |  |  |  |  |  | (i) one ordinary share and (ii) two warrants to purchase one ordinary share each, at a purchase price of $5.02 per unit (“November 2020 Warrants”). The November 2020 Warrants have an exercise price of $5.02 per ordinary share, will be exercisable upon issuance and will expire five years from the date of issuance. |  |  |  |  |  |  |  |  |
Gross proceeds (in Dollars) | $ |  |  |  |  | $ 10,210 |  |  |  |  |  |  |  | $ 4,200 |  |  |  |  |  |  |  |  |
Exercise warrants |  |  |  |  |  |  |  |  | 1,004,494 |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of aggregate shares |  |  |  |  | 3,546,100 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants exercise price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,630 |
April 2020 Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase agreement, description |  |  |  |  |  |  |  |  |  |  | the Company entered into a definitive securities purchase agreement (the “April 2020 Purchase Agreement”) with institutional investors to purchase of 4,166,168 units, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) one Series B warrant to purchase one ordinary share, at a purchase price of $0.2999 per unit. The Series B warrants have an exercise price of $0.43 per ordinary share, are exercisable upon issuance and expire five years from the date of issuance. The offering resulted in gross proceeds to the Company of approximately $1,250. The closing of the sale of the securities took place on April 3, 2020. After the closing of the April 2020 Purchase Agreement and until the Approval Date, all pre-funded warrants were exercised. In addition, 4,166,168 of the Series B warrants were exercised pursuant to a cashless exercise mechanism as described in the April 2020 Purchase Agreement for no further consideration to the Company. As of the Approval Date, all Series B warrants were exercised. |  |  |  |  |  |  |  |  |  |  |
March 2021 Financing Round [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |  |
Description of private offering |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an aggregate of 44,331 units, as follows: (a) 35,242 units at a price of $183,82 per unit, consisting of (i) one ordinary share of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the “2021 Series A Warrants”) and a Series B Warrant (the “2021 Series B Warrants” and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase half the number of units, and (b) 9,089 pre-funded units at a price of $183.794 per unit, consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant. |  |  |  |  |  |
Warrants and exercise |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |  |
June 2022 Financing Round [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of private offering |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | the Company completed the June 2022 Private Placement with an investor for gross proceeds of $10,210, providing for the issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the “June 2022 Warrants”), and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) two June 2022 Warrants. |  |  |  |  |  |
November 2020 Financing Round [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  | 835,447 |  |  |  |  |  |  |  |  |
Series A Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ordinary shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,929 |  |  |  |
Warrants and exercise |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 385 |  |  |  |
June 2022 Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) | $ / shares | $ 68.38 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Date of issuance | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ADS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ordinary shares issued |  |  |  |  |  |  |  |  |  | 140 |  |  |  |  |  |  |  |  |  |  |  |
Warrants [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,004,494 |  |  |  |
Pre-funded warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,211,100 |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ordinary shares issued |  |  |  |  |  |  |  | 1,800,000,000 |  |  |  |  |  | 750,000,000 | 500,000,000 |  |  |  |  |  |  |
Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ordinary shares issued |  |  |  |  |  |  |  | 3,600,000,000 |  |  |  |  |  | 1,800,000,000 | 750,000,000 |  |  |  |  |  |  |
Warrants [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pre-funded warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,846 |  | 4,544 |  |  |  |
Share issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,846 |  |  |  |  |
Ordinary shares [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  | 1,423 |  | 923 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,134 | 13,858 |  |
Series A Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 128,156 |  |  |  |
Exercise price (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 183,820 |  | $ 7.07 |  |  |  |
Warrants and exercise |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 118,156 |  |  |  |
Series B Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 275,600 |  | $ 10.6 |  |  |  |
Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants and exercise |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,211,100 |  |  |  |  |

X
- Definition The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 33 -IssueDate 2023-01-01 -Paragraph 70 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The exercise price of share options granted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2023-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ExercisePriceShareOptionsGranted2019
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares issued by the entity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 106 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_NumberOfSharesIssued
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of shares issued by the entity, for which full payment has been received. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 79 -Subparagraph a -Clause ii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_NumberOfSharesIssuedAndFullyPaid
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | sprcy_DateOfIssuance
Namespace Prefix: | sprcy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of private offering. + References No definition available. + Details
Name: | sprcy_DescriptionOfPrivateOffering
Namespace Prefix: | sprcy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | sprcy_DescriptionOfReverseShareSplit
Namespace Prefix: | sprcy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | sprcy_EquityDetailsLineItems
Namespace Prefix: | sprcy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise of Pre-funded warrants. + References No definition available. + Details
Name: | sprcy_ExerciseOfPrefundedWarrants
Namespace Prefix: | sprcy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gross proceeds. + References No definition available. + Details
Name: | sprcy_GrossProceeds
Namespace Prefix: | sprcy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The issuance of aggregate shares. + References No definition available. + Details
Name: | sprcy_IssuanceOfAggregateShares
Namespace Prefix: | sprcy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Issuance of shares. + References No definition available. + Details
Name: | sprcy_IssuanceOfShares
Namespace Prefix: | sprcy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represent of having no par value per share. + References No definition available. + Details
Name: | sprcy_NoParValuePerShare
Namespace Prefix: | sprcy_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | sprcy_PurchaseAgreementsDescription
Namespace Prefix: | sprcy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represent the number of stock issued during period reverse stock splits. + References No definition available. + Details
Name: | sprcy_StockIssuedDuringPeriodReverseStockSplits
Namespace Prefix: | sprcy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | sprcy_WarrantsAndExercise
Namespace Prefix: | sprcy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrants exercise price. + References No definition available. + Details
Name: | sprcy_WarrantsExercisePrice
Namespace Prefix: | sprcy_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | sprcy_AgreementTypeAxis=sprcy_AprilTwoThousandTwentyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CreationDateAxis=sprcy_June2022FinancingRoundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CreationDateAxis=sprcy_November2020FinancingRoundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_SeriesAWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_June2022WarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_ADSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=ifrs-full_WarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |